Q3 2025
Released Nov 6, 2025, after the close
10-Q filed Nov 6, 2025, 37 days after period end · 0001237831-25-000031
Q3 2025 · 10-Q
Revenue$769.05M$769.05M +22.9% vs Q3 2024+3.2% vs Q2 2025
Net Income$118.97M$118.97M +129.5% vs Q3 2024−41.4% vs Q2 2025
EPS Diluted$0.88$0.88 +131.6% vs Q3 2024−40.9% vs Q2 2025
Operating Income$137,363,000+185.6%
Operating Cash Flowderived$249,695,000+22.6%
Free Cash Flowderived$213,878,000+32.3%
Margins · derived
Operating margin17.9%+10.2 pt vs Q3 2024
Net margin15.5%+7.2 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $769.05M | $625.71M | $383.64M | $254.15M |
| Net Income | $118.97M | $51.84M | $998.00K | $47.43M |
| EPS Diluted | $0.88 | $0.38 | $0.01 | $0.47 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Globus Medical Inc · CIK 1237831 · Engraved from SEC EDGAR